The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Zandoriah teriparatide BiosimilarAdditional monitoring | CinnaGen Co Unipessoal LDA | Osteoporosis; Osteoporosis, Postmenopausal | 🇪🇺 EU 2026-04-27 | Order → |
| Saphnelo anifrolumab-fnia New biologic | Astrazeneca Ab | 🇺🇸 US 2026-04-24 | Order → | |
| Fubelv etanercept BiosimilarAdditional monitoring | Biosimilar Collaborations Ireland Limited | Arthritis, Rheumatoid; Arthritis, Juvenile; Arthritis, Psoriatic; Axial Spondyloarthritis; Non-Radiographic Axial Spondyloarthritis; Spondylitis, Ankylosing; Ps | 🇪🇺 EU 2026-04-23 | Order → |
| Palsonify paltusotine OrphanAdditional monitoring | Crinetics Pharmaceuticals Europe GmbH | Acromegaly | 🇪🇺 EU 2026-04-23 | Order → |
| Poherdy pertuzumab BiosimilarAdditional monitoring | Organon N.V. | Breast Neoplasms | 🇪🇺 EU 2026-04-23 | Order → |
| Rhapsido remibrutinib Additional monitoring | Novartis Europharm Limited | Urticaria | 🇪🇺 EU 2026-04-23 | Order → |
| Idvynso doravirine, islatravir New molecular entity | Msd | 🇺🇸 US 2026-04-20 | Order → | |
| mCombriax influenza mRNA vaccine;COVID-19 mRNA vaccine Additional monitoring | Moderna Biotech Spain, S.L. | Influenza, Human; COVID-19 virus infection | 🇪🇺 EU 2026-04-20 | Order → |
| Ojemda tovorafenib OrphanConditionalAdditional monitoring | Ipsen Pharma | Glioma | 🇪🇺 EU 2026-04-20 | Order → |
| Enflonsia clesrovimab Additional monitoring | Merck Sharp Dohme Limited | Respiratory Syncytial Virus Vaccines | 🇪🇺 EU 2026-04-15 | Order → |
| Foundayo orforglipron calcium New molecular entity | Eli Lilly And Co | 🇺🇸 US 2026-04-01 | Order → | |
| Epinephrine epinephrine | Baxter Hlthcare Corp | 🇺🇸 US 2026-03-30 | Order → | |
| Supemtek trivalent influenza vaccine (recombinant, prepared in cell culture) | Sanofi Winthrop Industrie | Influenza, Human | 🇪🇺 EU 2026-03-30 | Order → |
| Ponlimsi denosumab-adet Biosimilar | Teva Pharmaceuticals, Inc. | 🇺🇸 US 2026-03-27 | Order → | |
| Awiqli Flextouch insulin icodec New biologic | Novo Nordisk Inc | 🇺🇸 US 2026-03-26 | Order → | |
| Fylrevy estetrol Additional monitoring | Gedeon Richter Plc. | Menopause | 🇪🇺 EU 2026-03-26 | Order → |
| Ilumira lutetium (177Lu) chloride Additional monitoring | Shine Europe B.V. | Radionuclide Imaging | 🇪🇺 EU 2026-03-26 | Order → |
| Kayshild semaglutide ConditionalAdditional monitoring | Novo Nordisk A/S | Non-alcoholic Fatty Liver Disease; Liver Cirrhosis | 🇪🇺 EU 2026-03-26 | Order → |
| Kygevvi doxecitine;doxribtimine OrphanPRIMEExceptional circumstances | UCB Pharma | Mitochondrial Diseases | 🇪🇺 EU 2026-03-26 | Order → |
| Lifyorli (Copackaged) relacorilant New molecular entity | Corcept Therap | 🇺🇸 US 2026-03-25 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.